1.40
price down icon3.45%   -0.05
after-market After Hours: 1.45 0.05 +3.57%
loading
Erasca Inc stock is traded at $1.40, with a volume of 4.01M. It is down -3.45% in the last 24 hours and down -2.10% over the past month. Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
See More
Previous Close:
$1.45
Open:
$1.449
24h Volume:
4.01M
Relative Volume:
2.42
Market Cap:
$396.61M
Revenue:
-
Net Income/Loss:
$-125.04M
P/E Ratio:
-1.7073
EPS:
-0.82
Net Cash Flow:
$-122.99M
1W Performance:
+14.75%
1M Performance:
-2.10%
6M Performance:
-51.05%
1Y Performance:
-43.55%
1-Day Range:
Value
$1.34
$1.45
1-Week Range:
Value
$1.06
$1.47
52-Week Range:
Value
$1.01
$3.45

Erasca Inc Stock (ERAS) Company Profile

Name
Name
Erasca Inc
Name
Phone
(858) 465-6511
Name
Address
10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO
Name
Employee
129
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
ERAS's Discussions on Twitter

Compare ERAS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ERAS
Erasca Inc
1.40 345.61M 0 -125.04M -122.99M -0.82
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Erasca Inc Stock (ERAS) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-26-25 Initiated Raymond James Outperform
Nov-18-24 Initiated Jefferies Buy
Mar-11-24 Initiated CapitalOne Overweight
Jan-05-24 Downgrade BofA Securities Buy → Neutral
Oct-11-23 Initiated H.C. Wainwright Buy
Mar-30-23 Initiated Mizuho Buy
Feb-24-23 Initiated Goldman Buy
Feb-03-23 Upgrade Morgan Stanley Equal-Weight → Overweight
View All

Erasca Inc Stock (ERAS) Latest News

pulisher
03:52 AM

Deutsche Bank AG Boosts Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World

03:52 AM
pulisher
May 30, 2025

Discover May 2025's Top Penny Stocks - simplywall.st

May 30, 2025
pulisher
May 29, 2025

Bank of America Corp DE Has $4.88 Million Stock Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World

May 29, 2025
pulisher
May 29, 2025

Precision Oncology Pioneer Erasca Sets Major Investor Presentations at Jefferies and Goldman Sachs Conferences - Stock Titan

May 29, 2025
pulisher
May 26, 2025

Erasca, Inc. (NASDAQ:ERAS) Shares Sold by Janus Henderson Group PLC - Defense World

May 26, 2025
pulisher
May 24, 2025

D. E. Shaw & Co. Inc. Has $927,000 Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World

May 24, 2025
pulisher
May 22, 2025

Northern Trust Corp Boosts Stock Position in Erasca, Inc. (NASDAQ:ERAS) - Defense World

May 22, 2025
pulisher
May 21, 2025

Erasca, Inc. (NASDAQ:ERAS) Given Average Rating of “Buy” by Analysts - Defense World

May 21, 2025
pulisher
May 20, 2025

Erasca Inc (NASDAQ: ERAS) Could Pass $5 In One Year Stock Forecast - Stocksregister

May 20, 2025
pulisher
May 18, 2025

Price T Rowe Associates Inc. MD Buys 10,899 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World

May 18, 2025
pulisher
May 17, 2025

HC Wainwright Has Positive Forecast for Erasca Q2 Earnings - Defense World

May 17, 2025
pulisher
May 14, 2025

Erasca (ERAS) Target Price Adjusted by Guggenheim Analyst | ERAS Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

FDA clears Erasca’s new cancer drug ERAS-0015 By Investing.com - Investing.com India

May 14, 2025
pulisher
May 13, 2025

Erasca (ERAS) Advances RAS-Targeting Therapies with New Clinical Developments | ERAS Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Erasca Reports First Quarter 2025 Business Updates and Financial Results - The Manila Times

May 13, 2025
pulisher
May 13, 2025

Erasca, Inc. Advances RAS-Targeting Pipeline with IND Clearances and Extended Cash Runway - Nasdaq

May 13, 2025
pulisher
May 13, 2025

Erasca Advances Two Novel Cancer Drugs to Clinic, Secures 3-Year Cash Runway with $411M - Stock Titan

May 13, 2025
pulisher
May 13, 2025

Erasca Seeks Partner for Naporafenib to Extend Cash Runway - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Erasca (ERAS) Advances RAS-Targeting Drugs with FDA Clearance | - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Erasca (ERAS) Advances RAS-Targeting Drugs with FDA Clearance | ERAS Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

FDA clears Erasca’s new cancer drug ERAS-0015 - Investing.com

May 13, 2025
pulisher
May 13, 2025

Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway - The Manila Times

May 13, 2025
pulisher
May 13, 2025

Dimensional Fund Advisors LP Increases Position in Erasca, Inc. (NASDAQ:ERAS) - Defense World

May 13, 2025
pulisher
May 13, 2025

Hsbc Holdings PLC Purchases 10,458 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World

May 13, 2025
pulisher
May 12, 2025

Erasca, Inc. (NASDAQ:ERAS) Shares Bought by Tower Research Capital LLC TRC - Defense World

May 12, 2025
pulisher
May 12, 2025

Erasca (ERAS) Expected to Announce Quarterly Earnings on Wednesday - Defense World

May 12, 2025
pulisher
May 08, 2025

MetLife Investment Management LLC Has $283,000 Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World

May 08, 2025
pulisher
May 07, 2025

Erasca to Present at the Bank of America Securities Health Care Conference - TradingView

May 07, 2025
pulisher
May 06, 2025

Recurrent Glioblastoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail

May 06, 2025
pulisher
May 06, 2025

Invesco Ltd. Acquires 11,290 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World

May 06, 2025
pulisher
May 06, 2025

Barclays PLC Boosts Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World

May 06, 2025
pulisher
May 06, 2025

Wells Fargo & Company MN Sells 73,262 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World

May 06, 2025
pulisher
May 02, 2025

Erasca Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView

May 02, 2025
pulisher
May 02, 2025

HC Wainwright Reaffirms Buy Rating for Erasca (NASDAQ:ERAS) - Defense World

May 02, 2025
pulisher
May 01, 2025

Holdings of Erasca Inc (ERAS) are aligned with the stars - Sete News

May 01, 2025
pulisher
Apr 30, 2025

Analyze Erasca Inc (NASDAQ: ERAS) Before Investing. - Stocksregister

Apr 30, 2025
pulisher
Apr 30, 2025

Erasca Inc (ERAS)’s stock price range in the last year - uspostnews.com

Apr 30, 2025
pulisher
Apr 30, 2025

Legal & General Group Plc Buys 64,574 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World

Apr 30, 2025
pulisher
Apr 30, 2025

Erasca (ERAS) Showcases Innovative RAS-Targeting Treatments at C - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Erasca presents new RAS-targeting franchise data at AACR meeting - TipRanks

Apr 30, 2025
pulisher
Apr 30, 2025

XTX Topco Ltd Purchases Shares of 55,361 Erasca, Inc. (NASDAQ:ERAS) - Defense World

Apr 30, 2025
pulisher
Apr 29, 2025

Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting - The Manila Times

Apr 29, 2025
pulisher
Apr 29, 2025

New Cancer Drug Data: Erasca's RAS Inhibitors Show Best-in-Class Potential at AACR 2025 - Stock Titan

Apr 29, 2025
pulisher
Apr 29, 2025

Erasca Inc (NASDAQ: ERAS) Shares Are Down -44.22% Year To Date. - Marketing Sentinel

Apr 29, 2025
pulisher
Apr 29, 2025

Checking in on Erasca Inc (ERAS) after recent insiders movement - knoxdaily.com

Apr 29, 2025
pulisher
Apr 28, 2025

Carclo (LON:CAR) Trading Up 3.1% – Here’s Why - The AM Reporter

Apr 28, 2025
pulisher
Apr 25, 2025

Erasca, Inc: Carving A Different Niche In RAS Signaling (NASDAQ:ERAS) - Seeking Alpha

Apr 25, 2025
pulisher
Apr 24, 2025

Check out these key findings about Erasca Inc (ERAS) - Sete News

Apr 24, 2025
pulisher
Apr 24, 2025

Analytical Overview: Erasca Inc (ERAS)’s Ratios Tell a Financial Story - DWinneX

Apr 24, 2025
pulisher
Apr 23, 2025

Erasca Inc (ERAS) may enjoy gains as insiders got busy in the recent days - knoxdaily.com

Apr 23, 2025
pulisher
Apr 23, 2025

ERAS’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com

Apr 23, 2025

Erasca Inc Stock (ERAS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Cap:     |  Volume (24h):